0000899243-20-000615.txt : 20200106
0000899243-20-000615.hdr.sgml : 20200106
20200106181049
ACCESSION NUMBER: 0000899243-20-000615
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191231
FILED AS OF DATE: 20200106
DATE AS OF CHANGE: 20200106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON KENNETH ERLAND
CENTRAL INDEX KEY: 0001743774
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38536
FILM NUMBER: 20511439
MAIL ADDRESS:
STREET 1: C/O XERIS PHARMACEUTICALS, INC.
STREET 2: 180 N. LASALLE STREET, SUITE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001346302
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203352427
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
BUSINESS PHONE: 844-445-5704
MAIL ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-12-31
0
0001346302
XERIS PHARMACEUTICALS INC
XERS
0001743774
JOHNSON KENNETH ERLAND
C/O XERIS PHARMACEUTICALS, INC.
180 N. LASALLE STREET, SUITE 1600
CHICAGO
IL
60601
0
1
0
0
See Remarks
Common Stock
2019-12-31
5
A
0
E
286
5.99
A
3705
D
These shares were purchased due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from July 1, 2019 through December 31, 2019.
In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on December 31, 2019.
Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs
/s/ Beth Hecht, as Attorney-in-Fact
2020-01-06